Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

M. Vannucchi, Alessandro; Kiladjian, Jean‐Jacques; Grießhammer, Martin; Masszi, Tamás; Durrant, Simon; Passamonti, Francesco; Harrison, Claire; Pane, Fabrizio; Zachée, Pierre; A. Mesa, Ruben; He, Shui; M. Jones, Mark; M. Garrett, William; Li, Jingjin; Pirron, Ulrich; Habr, Dany; Verstovšek, Srđan

doi:10.1056/nejmoa1409002

Public

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Published in New England Journal of Medicine • Jan 28, 2015

Authors:

Alessandro M. Vannucchi

Jean‐Jacques Kiladjian

Martin Grießhammer

Abstract

BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemi...

Subject

Medicine

Polycythemia vera

Ruxolitinib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!